- Home
- IMRN vs SNTI Comparison
IMRN vs SNTI Comparison
Compare IMRN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- SNTI
- Stock Information
- Founded
- IMRN 1994
- SNTI 2016
- Country
- IMRN Australia
- SNTI United States
- Employees
- IMRN N/A
- SNTI N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- SNTI Health Care
- Exchange
- IMRN Nasdaq
- SNTI Nasdaq
- Market Cap
- IMRN 9.2M
- SNTI 39.6M
- IPO Year
- IMRN N/A
- SNTI N/A
- Fundamental
- Price
- IMRN $1.83
- SNTI $1.39
- Analyst Decision
- IMRN Strong Buy
- SNTI Strong Buy
- Analyst Count
- IMRN 1
- SNTI 2
- Target Price
- IMRN $5.00
- SNTI $8.50
- AVG Volume (30 Days)
- IMRN 43.6K
- SNTI 126.3K
- Earning Date
- IMRN 08-29-2025
- SNTI 11-13-2025
- Dividend Yield
- IMRN N/A
- SNTI N/A
- EPS Growth
- IMRN N/A
- SNTI N/A
- EPS
- IMRN N/A
- SNTI N/A
- Revenue
- IMRN $4,777,422.00
- SNTI N/A
- Revenue This Year
- IMRN N/A
- SNTI N/A
- Revenue Next Year
- IMRN N/A
- SNTI $150.00
- P/E Ratio
- IMRN N/A
- SNTI N/A
- Revenue Growth
- IMRN 48.63
- SNTI N/A
- 52 Week Low
- IMRN $1.50
- SNTI $1.26
- 52 Week High
- IMRN $2.87
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- IMRN 50.67
- SNTI 38.48
- Support Level
- IMRN $1.80
- SNTI $1.33
- Resistance Level
- IMRN $1.94
- SNTI $1.39
- Average True Range (ATR)
- IMRN 0.07
- SNTI 0.08
- MACD
- IMRN -0.00
- SNTI 0.01
- Stochastic Oscillator
- IMRN 42.11
- SNTI 37.14
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.